Lecanemab: A Breakthrough in Alzheimer’s Disease Treatment

Lecanemab is a groundbreaking treatment for Alzheimer’s disease, showing significant promise in slowing cognitive decline in patients with early-stage disease. Lecanemab is the most recent monoclonal antibody to target beta-amyloid and is licensed only for the treatment of mild cognitive impairment or mild dementia associated with Alzheimer's disease. Lecanemab represents a fresh approach to targeting the pathophysiology underlying the condition, and the encouraging outcomes of the Phase 3 trial provide hope to patients and their families. Although more research is need to determine lecanemab's safety and efficacy, the results of the Phase 3 trial suggest that it could greatly improve AD treatment options. This review explores the mechanism of action, clinical trial data, potential impacts, and future directions for this monoclonal antibody therapy.